Riken Genesis and Burning Rock Biotech (BNR) announced that the OncoGuide OncoScreen Plus CDx System based on OncoScreen Plus to be used as a companion diagnostic for AstraZeneca’s (AZN) capivasertib has received manufacturing and marketing approval from Japan’s Ministry of Health, Labour and Welfare.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BNR: